3.1.1 volunteered for the clinical research and signed informed consent. 3.1.2 aged 18-70,
expected lifetime > 3 months. 3.1.3 gender not limited. 3.1.4 late lung cancer (stage
IIIb/IV), (IV) with esophageal carcinoma, and melanoma (advanced), no other effective cure
Treatment method can be selected patients. 3.1.5 biopsy IHC confirmed positive expression,
NY - ESO - 1 or 50% of the tumor cells IHC staining in 2 + and/or 3 +.Organization based on
time in the group in the year before, can be a tumor tissue, can also be a pleural effusion
3.2.1 this study used in the process of cell preparation ingredients allergy, such as
3.2.2 used within a week of tyrosine kinase inhibitors (the treatment such as, for it), or
other cancer drugs.
3.2.3 is systemic anti-cancer therapy, including immune therapy, such as accept the immune
cells within a month back to lose Therapy or biological treatment.6 weeks used cancer
associated with tumor immune single resistance (including the PD, PD - L1 and - 1 CTLA 4
single resistance). 3.2.4 have vital organs, such as cardiovascular, respiratory system
disease, myocardial infarction, myocardial ischemia, the coronary artery bypass History or
coronary ischemia symptoms, obstructive or restrictive lung disease. 3.2.5 the patient's
immune tolerance is poor, may on the immune cells in treatment of the reaction of low or
prone to toxic reactions.
3.2.6 always have autoimmune and immunodeficiency disease. 3.2.7 radiation pneumonitis.
3.2.8 depends on oxygen. 3.2.9 four weeks into the set of other therapeutic studies or
clinical trials. 3.2.10 used experimental vaccine in two months 3.2.11 systemic
corticosteroids used within two weeks, hydroxyurea or immune inhibitors (such as IL - 2,
Interferons alpha, IFN - gamma, GSF, mTOR inhibitors, ring spore element, etc.).Recently or
are using suction The sex hormone. 3.2.12 year have chronic or recurrent severe autoimmune
diseases. 3.2.13 uncontrolled active infection. 3.2.14 2-4 acute or persistent during graft
versus host disease (GVHD). 3.2.15 serious heart disease, after treatment of the disease is
still unstable, into the group of the first six months after myocardial infarction, and
congestion Heart failure, unstable angina, symptoms of pericardial effusion or unstable
3.2.18 always suffer from other cancers, but does not include: A. basal cell carcinoma and
squamous cell carcinoma after active treatment, the wound healed completely.
B. the cervical or breast carcinoma in situ cure for at least three years. C. primary
malignant tumors were removed completely, completely relieve five years or more.
3.2.19 accompanied by primary or secondary brain tumor patients. 3.2.20 the mentally
disabled. 3.2.21 doubt or have alcohol and drug abuse history. 3.2.22 physicians determine
cannot or may not be able to complete the test subjects.
3.2.23 any not listed may interfere with the patient to participate in the active disease.